Joana Carvalho, PhD, managing science editor —

A new pharmacological strategy was able to minimize many cognitive and behavioral defects in mice with fragile X syndrome. Researchers now believe this may be a promising therapeutic strategy for this disease and other brain disorders. The findings from the study, “Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range…

Irritable behavior in patients with fragile X syndrome significantly improved after receiving aripiprazole, an antipsychotic medication previously approved by the U.S. Food and Drug Administration (FDA) to treat other psychotic conditions. The study, “A prospective open-label of aripiprazole in fragile X syndrome,” was published in Psychopharmacology. Fragile…